{"id":44440,"date":"2025-10-18T11:38:11","date_gmt":"2025-10-18T11:38:11","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2025\/10\/18\/why-hims-hers-stock-is-failing-to-retain-menopause-gains-and-what-comes-next\/"},"modified":"2025-10-18T11:38:11","modified_gmt":"2025-10-18T11:38:11","slug":"why-hims-hers-stock-is-failing-to-retain-menopause-gains-and-what-comes-next","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2025\/10\/18\/why-hims-hers-stock-is-failing-to-retain-menopause-gains-and-what-comes-next\/","title":{"rendered":"Why Hims & Hers stock is failing to retain menopause gains and what comes next?"},"content":{"rendered":"
<\/div>\n

Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments \u2013 a large and underserved market.<\/p>\n

However, the rally is fading rather quickly. On Friday, the telehealth stock tanked another 15% as Andrew Dudum, the company\u2019s chief executive, confirmed he\u2019s sold over $11 million worth of its shares.  <\/p>\n

Including today\u2019s decline, Hims & Hers stock is down roughly 30%<\/a> versus its year-to-date high in February.<\/p>\n

Why Dudum\u2019s sales are bearish for Hims & Hers stock<\/h2>\n

While Dudum\u2019s sale of HIMS stock was pre-scheduled, the optics are hard to ignore.<\/p>\n

He unloaded more than 175,000 shares \u2013 including exercised options and vested restricted stock \u2013  just days after the company\u2019s menopause expansion announcement.<\/p>\n

This brings his total insider sales<\/a> to over $40 million in the past three months. For a company still chasing consistent profitability, such aggressive insider selling raises red flags.<\/p>\n

Investors often interpret insider sales as a lack of conviction in future growth, especially when they follow bullish news.<\/p>\n

The timing has cast a shadow over Hims & Hers\u2019 strategic narrative, suggesting even top leadership may be more focused on monetizing gains than riding the telehealth stock for the long term.<\/p>\n

Why HIMS shares are unattractive heading into 2026<\/h2>\n

Beyond insider selling, Hims & Hers faces structural challenges that make its stock vulnerable.<\/p>\n

The company trades at a premium forward price-to-earnings (P\/E) multiple of 105 \u2013 significantly higher than its peers as well as the best-of-breed artificial intelligence (AI) stocks, even including Nvidia.<\/p>\n

Thin margins and persistent net losses make that valuation even more concerning. HIMS\u2019 direct-to-consumer model, while innovative, is expensive to scale \u2013 especially in a competitive telehealth landscape where customer acquisition costs are rising.<\/p>\n

Meanwhile, regulatory scrutiny around digital prescriptions and compounded hormone therapies could also pose headwinds.<\/p>\n

Investors should also note that the menopause market \u2013 while large \u2013 is fragmented and medically complex, requiring trust and clinical depth that HIMS has yet to fully establish.<\/p>\n

With macro pressures mounting and profitability elusive, Hims & Hers’ lofty valuation looks increasingly difficult to defend.<\/p>\n

How to play Hims & Hers at current levels<\/h2>\n

Hims & Hers has built its brand on sleek marketing and rapid product rollouts, but sustaining investor enthusiasm requires more than buzz.<\/p>\n

The menopause pivot was a smart strategic move, yet the CEO\u2019s stock sale has undermined its impact. As 2026 approaches, investors will be watching for signs of durable growth, margin expansion, and operational discipline.<\/p>\n

Until then, Hims & Hers may remain a battleground stock \u2013 caught between retail optimism and institutional skepticism. For now, HIMS stock sell-off serves as a reminder that momentum fades fast when leadership signals mixed priorities.<\/p>\n

The post Why Hims & Hers stock is failing to retain menopause gains and what comes next?<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments \u2013 a large and underserved market. However, the rally is fading rather quickly. On Friday, the telehealth stock tanked another 15% as Andrew Dudum, the company\u2019s chief executive, confirmed he\u2019s sold over $11 million <\/p>\n","protected":false},"author":1,"featured_media":44441,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":{"0":"post-44440","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/44440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=44440"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/44440\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/44441"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=44440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=44440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=44440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}